

DIVISION OF CORPORATION FINANCE

May 26, 2020

Lisa Walters-Hoffert Cheif Financial Officer Dare Bioscience, Inc. 3655 Nobel Drive, Suite 260 San Diego, CA 92122

> Re: Dare Bioscience, Inc. Registration Statement on Form S-3 Filed May 15, 2020 File No. 333-238299

Dear Ms. Walters-Hoffert:

We have limited our review of your registration statement to the issue we have addressed in our comment below. In our comment we have asked you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments.

## Form S-3 filed May 15, 2020

## Exclusive Forum By-law Provision, page 14

1. We note that Section 5.9 of the Second Amended and Restated By-Laws of Dare Bioscience, Inc. includes a forum selection provision that identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any "derivative action or proceeding brought on behalf of the corporation." Please disclose whether this provision applies to actions arising under the Securities Act or Exchange Act. In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the Lisa Walters-Hoffert Dare Bioscience, Inc. May 26, 2020 Page 2

> provision applies to Securities Act claims, please also revise your prospectus to state that there is uncertainty as to whether a court would enforce such provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If this provision does not apply to actions arising under the Securities Act or Exchange Act, please also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Securities Act or Exchange Act.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Laura Crotty at (202) 551-7614 or Celeste Murphy at (202) 551-3257 with any other questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Edwin Astudillo